novo nordisk cuts prices for its glp-1 drugs. Wegovy in Half While Stock Sits Near a 52-Week Low Novo Nordisk to Cut U.S.

That will require a larger trial with longer duration of treatmentit deserves a high priority given the current results

[DOI] [PubMed] [Google Scholar] 81

2015;308(5):E41425

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

[7] These medications have also been linked to improvements in blood pressure and cholesterol levels, enhancing overall metabolic health and potentially reducing the risk of heart failure and kidney disease

Diabetes Obes Metab 2023;25:101123.PubMed 112